Gland Pharma Limited (NSE:GLAND)
1,681.10
+5.20 (0.31%)
Jan 28, 2026, 1:39 PM IST
Gland Pharma Revenue
Gland Pharma had revenue of 14.87B INR in the quarter ending September 30, 2025, with 5.76% growth. This brings the company's revenue in the last twelve months to 58.01B, down -1.51% year-over-year. In the fiscal year ending March 31, 2025, Gland Pharma had annual revenue of 56.17B, down -0.85%.
Revenue (ttm)
58.01B
Revenue Growth
-1.51%
P/S Ratio
4.76
Revenue / Employee
13.33M
Employees
4,351
Market Cap
276.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 56.17B | -482.18M | -0.85% |
| Mar 31, 2024 | 56.65B | 20.40B | 56.29% |
| Mar 31, 2023 | 36.25B | -7.76B | -17.64% |
| Mar 31, 2022 | 44.01B | 9.38B | 27.08% |
| Mar 31, 2021 | 34.63B | 8.30B | 31.51% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Glenmark Pharmaceuticals | 159.97B |
| Ipca Laboratories | 93.59B |
| Piramal Pharma | 89.36B |
| Emcure Pharmaceuticals | 84.49B |
| Alembic Pharmaceuticals | 70.83B |
| Laurus Labs | 67.22B |
| Ajanta Pharma | 49.73B |
| NATCO Pharma | 43.90B |
Gland Pharma News
- 19 hours ago - Gland Pharma Ltd (NSE:GLAND) Q3 2026 Earnings Report Preview: What To Expect - GuruFocus
- 5 days ago - Pharma sector stocks today, Jan 23: Dr. Reddy’s Lab jumps 2.14%, Gland Pharma falls 1.71%, Torrent Pharma down 0.80% - Business Upturn
- 20 days ago - Gland Pharma shares surge nearly 4% after getting USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC) - Business Upturn
- 20 days ago - Top stocks to watch today, January 8: Infosys, Tata Steel, HUDCO, Gland Pharma, Angel One, Cipla and more - Business Upturn
- 20 days ago - Gland Pharma receives USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC) - Business Upturn
- 3 months ago - Nomura cautious on Gland Pharma, trims estimates post Q2 miss but sees long-term visibility - Business Upturn
- 3 months ago - Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 3 months ago - Q2 2026 Gland Pharma Ltd Earnings Call Transcript - GuruFocus